Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations

AIDS

Volumn 18, Issue 8, 2004, Pages 1137-1146

  Clotet, Bonaventura ^a   Raffi, François ^b   Cooper, David ^c   Delfraissy, Jean François ^d   Lazzarin, Adriano ^e   Moyle, Graeme ^f   Rockstroh, Jürgen ^g   Soriano, Vincent ^h   Schapiro, Jonathan ⁱ  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BICÊTRE HOSPITAL   (France)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BONN   (Germany)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiretroviral therapy; Enfuvirtide; Fusion inhibitors; HIV; Salvage therapy; Treatment recommendations; Treatment experienced patients

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIHISTAMINIC AGENT; ENFUVIRTIDE;

ARTICLE; CHILL; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GUILLAIN BARRE SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INFECTION RESISTANCE; INJECTION PAIN; MEDICAL DECISION MAKING; NAUSEA; PATIENT EDUCATION; PNEUMONIA; PRACTICE GUIDELINE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; TREATMENT INDICATION; VOMITING;

CLINICAL TRIALS, PHASE III; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, INTRADERMAL; PATIENT EDUCATION; PEPTIDE FRAGMENTS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 2942596050     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200405210-00007     Document Type: Article

References (40)

1. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9:1051-1053.
2. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud CA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307.
3. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91:9770-9774.
4. Lalezari JP, Henry K, O'Hearn M, Montaner JSC, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003, 348:2175-2185.
5. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003, 348:2186-2195.
6. Cunningham C, Church J, Hughes M, Sista P, Palumbo P, Mofenson L, et al. Chronic subcutaneous T-20 (enfuvirtide) in HIV infected children: 48 week outcome. 40th Annual Meeting of the Infectious Diseases Society of America. Chicago, October 2002 [abstract 441].
7. Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, et al. Pharmacokinetics of enfuvirtide in pediatric HIV infected patients receiving combination therapy. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, July 2003 [abstract 841].
8. Cilliers T, Patience T, Papathanasopolous MA, Morris L. Sensitivity of HIV-1 subtype C isolates to the fusion inhibitor T-20 [abstract]. Antivir Thier 2003, 8(Suppl 1):S210.
9. Sista P, Melby T, Dhingra U, Cammack N, McKenna P, Dehertogh P, et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades [abstract]. Antivir Ther 2001, 6(Suppl 1):3-4.
10. Greenberg ML, Melby T, Sista P, DeMasi R, Cammack N, Salgo M, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 141].
11. Greenberg ML, McDanal CB, Stanfield-Oakley SA, Jin L, Tremblay C, Sista P, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 473].
12. Whitcomb JM, Huang W, Fransen S, Wrin T, Paxinos E, Toma J, et al. Analysis of baseline enfuvirtide (T20) susceptibility and coreceptor tropism in two Phase III study populations. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 557].
13. Labrosse B, Labernardière J-L, Dam E, Trouplin V, Skrabal K, Clavel F, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003, 77:1610-1613.
14. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by co-receptor specificity defined by the V3 loop of gp120. J Virol 2000, 74:8358-8367.
15. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2003, 99:16249-16254.
16. Zhang X, Lalezari JP, Badley A, Dorr A, Kolis S, Kinchelow T, et al. Assessment of drug-drug interaction potential of enfuvirtide in HIV-1 infected patients. Clin Pharmacol Ther 2004, in press.
17. Katlama C, Arastéh K, Clotet B, Cooper D, Henry K, Lalezari J, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd IAS Conference on HIV Rathogenesis and Treatment. Paris, July 2003 [abstract LB2].
18. Montaner J, DeMasi R, Delehanty J, Chung J, Gafoor Z, Salgo M. Analysis of virological response of enfuvirtide in TORO: implications for patient management [abstract]. Antivir Ther 2003, 8(Suppl 1):S212.
19. Emery S, Hales G, Birch C, Crowe S, Hoy J, Workman C, et al. CREST - A randomised comparison of genotype versus genotype plus virtual phenotype (VircoGEN II) HIV drug resistance testing. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 592].
20. Loveday C, Dunn DT, Green H, Rinehart A. A randomized controlled trial of phenotypic resistance testing in addition to genotypic resistance testing: the ERA trial [abstract]. Antivir Ther 2003, 8(Suppl 1):S188.
21. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002, 16:209-218.
22. Delfraissy J-F, Montaner J, Eron J, DeMasi R, Chung J, Drobnes C, et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients. Tenth Conference on Retroviruses and Opportunistic Infections. Boston 2003 [abstract 568].
23. Sista P, Melby T, Greenberg ML, DeMasi R, Kuritzkes D, Nelson M, et al. Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies [abstract]. Antivir Ther 2003, 8:S60.
24. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Wrol 1998, 72:986-993.
25. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905.
26. Sista P, Melby T, Greenberg ML, Davison D, Jin L, Mosier S, et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates [abstract]. Antivir Ther 2002, 7:S16-S17.
27. Trottier B, Arastéh K, Henry K, Katlama C, Lazzarin A, Montaner J, et al. Durability of response to enfuvirtide through 48 weeks in the TORO trials. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstract H-835].
28. Masquelier B, Neau D, Chene G, Larbere J, Birac V, Ragnaud JM, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2001, 28:309-312.
29. Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003, 8:279-287.
30. Cohen CJ, Clumeck N, Molina J-M, Thompson M, Patel K, Wintfield N, et al. Impact of enfuvirtide on health-related quality of life. 2nd IAS Conference on HIV Pathogenesis and Treatment Paris, July 2003 [abstract 1148].
31. Loufty M, Walmsley S, Mullin C, Perez G, Neaton J. CD4+ cell increase to highly active antiretroviral therapy (HAART) at one year is predictive of clinical outcome despite incomplete virological suppression [abstract]. Antivir Ther 2003, 8(Suppl 1):S218-S219.
32. Poveda E, Rodés B, Toro C, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002, 16:1959-1961.
33. Poveda E, Rodés B, Muñoz-Fernandez MA, Toro C, Martín-Carbonero L, Soriano V. Impact of viral genotype and phenotype on enfuvirtide response in HIV-infected patients. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, July 2003 [abstract 572].
34. Eron J, Delfraissy J-F, Kuritzkes D, Lange J, Stellbrink H-J, Cohen C, et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstract H-836].
35. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002, 16:327-335.
36. Cohen C, Hellinger J, Johnson M, Staszewski S, Wintfield N, Patel K, et al. Patient acceptance of self-injected enfuvirtide (T-20) at 8 and 24 weeks. HIV Clin Trials 2003, 4:347-357.
37. Ball RA, Kinchelow T. Injection site reactions (ISRs) with the HIV-1 fusion inhibitor enfuvirtide (T-20). J Am Acad Dermatol 2003, 49:826-831.
38. Piliero P, Fish DG, Preston S, Cunningham D, Kinchelow T, Salgo M, et al. Guillain-Barré syndrome associated with immune reconstitution. Clin Infect Dis 2003, 36:e111-e114.
39. Lambert DM, Johnson MR, Black PL, Ussery MA, Venetta T, DiMassimo E, et al. Antiviral activity and pharmacokinetics of T-20, an amphipathic helical peptide derived from gp41. XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.A.1080].
40. Myers SA, Selim A, McDaniel M, Hall R, Bartlett J, True AL, et al. A prospective clinical and histological examination of injection sites with the HIV fusion inhibitor enfuvirtide (ENF). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstract H-2015].